Loading...
XSHG600080
Market cap390mUSD
Dec 25, Last price  
7.58CNY
1D
-0.79%
1Q
24.47%
Jan 2017
-39.65%
Name

Ginwa Enterprise Group Inc

Chart & Performance

D1W1MN
XSHG:600080 chart
P/E
—
P/S
5.04
EPS
—
Div Yield, %
0.13%
Shrs. gr., 5y
2.28%
Rev. gr., 5y
-5.37%
Revenues
565m
-2.41%
794,552,020771,037,686308,274,003307,845,534522,221,004331,809,837327,428,993378,249,985460,193,983471,099,599712,790,078730,144,537666,645,492757,182,461745,161,287754,544,013668,180,334534,036,500579,374,501565,403,410
Net income
-43m
L
9,037,9810033,209,4170033,563,388165,555,05944,254,97845,594,44930,950,76625,384,13627,299,10353,462,80138,322,01225,902,67337,738,016033,459,505-42,890,580
CFO
61m
+15.16%
78,363,274000123,962,81037,418,41340,760,10091,018,37518,246,53443,959,62634,333,48030,330,52341,676,48642,865,56829,179,013111,445,50446,558,37030,594,67352,578,99360,548,425
Dividend
Jun 17, 20210.09 CNY/sh
Earnings
May 16, 2025

Profile

Ginwa Enterprise (Group) Inc. researches, develops, produces, and sells proprietary Chinese, biological, and chemical medicines in China. It offers orthopedic, immune, pediatric, antibiotic, digestive system, gynecological, cardiovascular, antipyretic, analgesic, antiviral, and other products. The company provides its products in the form of capsules, powders, and tablets. Ginwa Enterprise (Group) Inc. is based in Xi'an, China.
URL
http://www.ginwa.com.cn/
IPO date
Jun 12, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
565,403
-2.41%
579,375
8.49%
534,036
-20.08%
Cost of revenue
486,047
509,744
469,926
Unusual Expense (Income)
NOPBT
79,357
69,630
64,110
NOPBT Margin
14.04%
12.02%
12.00%
Operating Taxes
1,836
14,441
Tax Rate
2.31%
20.74%
NOPAT
77,521
55,189
64,110
Net income
(42,891)
-228.19%
33,460
 
Dividends
(3,725)
(33,594)
Dividend yield
0.13%
1.06%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
4,149
(3,991)
Long-term debt
10,859
23,393
Deferred revenue
246
278
Other long-term liabilities
15,845
14
58,459
Net debt
(1,115,458)
(754,483)
(654,977)
Cash flow
Cash from operating activities
60,548
52,579
30,595
CAPEX
(69,118)
Cash from investing activities
137,761
229,868
Cash from financing activities
(11,215)
FCF
357,336
(11,594)
86,937
Balance
Cash
677,277
579,635
650,986
Long term investments
449,040
202,390
Excess cash
1,098,047
753,056
624,284
Stockholders' equity
692,108
920,591
893,043
Invested Capital
967,592
932,673
1,078,763
ROIC
8.16%
5.49%
6.03%
ROCE
4.78%
4.12%
3.75%
EV
Common stock shares outstanding
389,914
373,270
373,270
Price
7.46
-4.48%
7.81
-8.44%
8.53
52.59%
Market cap
2,908,761
-0.22%
2,915,241
-8.44%
3,183,996
52.59%
EV
1,793,303
2,160,758
2,529,018
EBITDA
117,252
99,436
91,735
EV/EBITDA
15.29
21.73
27.57
Interest
4,442
1,191
2,183
Interest/NOPBT
5.60%
1.71%
3.41%